

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR, ESTABLISHMENT OF THE RISK MANAGEMENT COMMITTEE AND ESTABLISHMENT OF THE STRATEGY COMMITTEE

This announcement is made by the board of directors (the “**Board**”) of GenScript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Zhang Fangliang (章方良) (“**Dr. Zhang**”) has been appointed as an non-executive Director of the Company with effect from 2 May 2022. Upon the establishment of the risk management committee of the Board and the strategy committee of the Board as set out in this announcement below, Dr. Zhang has also been appointed as the chairman of the risk management committee and the strategy committee.

The biographical details and other information of Dr. Zhang are set out below:

Dr. Zhang Fangliang (章方良), aged 57, is the co-founder of the Company. He was appointed as a Director on 21 May 2015, redesignated as an executive Director and appointed as chairman on 24 August 2015, redesignated from an executive Director to a non-executive Director on 2 August 2020, resigned from a non-executive Director and chairman of the Board on 22 November 2020, and reappointed as a non-executive Director, appointed as chairman of the risk management committee of the Board and chairman of the strategy committee of the Board on 2 May 2022. Upon his appointment as our non-executive Director, he will be primarily responsible for the development, positioning, strategic planning and risk management of the Group. He is one of the founders and a director of Genscript Corporation. He is the former director, chairman, and chief executive officer of our non-wholly-owned subsidiary Legend Biotech Corporation (NASDAQ:

LEGN) from 27 May 2015 to 22 November 2020 and as its chief executive officer from 2 August 2020 to 22 November 2020. Dr. Zhang is currently the director of GenScript Bioscience (BVI) Limited, Genscript USA Incorporated, GenScript USA Holding, Inc., CustomArray, Inc., GenScript (Hong Kong) Limited, GenScript Biotech (Singapore) Pte. Ltd., GenScript Biotech (Netherlands) B.V., Nanjing GenScript Biotech Co., Ltd.* (南京金斯瑞生物科技有限公司), Jiangsu GenScript Biotech Co., Ltd.* (江蘇金斯瑞生物科技有限公司), Jinsikang Technology (Nanjing) Co., Ltd.* (金斯康科技(南京)有限公司), Bestzyme Biotech Corporation, Bestzyme Biotech Limited, Bestzyme USA Inc., Bestzyme Biotech HK Limited, GenScript International Limited, Bestzyme Biotech Inc., Nanjing Bestzyme Bioengineering Co., Ltd.* (南京百斯傑生物工程股份有限公司), Jinan Bestzyme Bio-Engineering Co., Ltd. (濟南百斯傑生物工程股份有限公司), Jinan Bestzyme biological engineering Co. Ltd., Downtown Branch Company* (濟南百斯傑生物工程股份有限公司市中分公司), Shandong Bestzyme Biotech Co., Ltd.* (山東百斯傑生物科技有限公司), Yangtze Investment (BVI) Limited, Yangtze Investment USA, Inc., Yangtze Holdings (BVI) Limited, Yangtze Investment (HK) Limited, Curegene Biotech Corporation, Curegene Biotech (BVI) Limited, Curegene Biotech (HK) Limited, Novagene Biotech (Cayman) Corporation and Maple Bio (Nanjing) Co., Ltd.* (楓楊生物研發(南京)有限公司).

Dr. Zhang has over 25 years of experience in the biotechnology industry. Prior to joining the Group, from 1995 to 2002, he worked as a postdoctoral research fellow and an associate principal scientist at Schering-Plough. Dr. Zhang worked in the tumour biology department during his postdoctoral research at Schering-Plough. Dr. Zhang was also one of the key team members for an anti-cancer drug, farnesyl transferase inhibitor. After Dr. Zhang's postdoctoral studies, he was recruited to the department of central nervous system and cardiovascular system at Schering-Plough. He became one of the project leaders focusing on G-protein coupled receptors and led a group of scientists to discover the drug target for a billion-dollar drug. As a result of this discovery, Dr. Zhang won a Presidential Award at Schering-Plough in 2001. From 2002 to August 2020, Dr. Zhang worked as the chief executive officer of the Company, where he was involved in a variety of key biotechnological research projects and provided guidance and directions to those biotechnological research projects. Dr. Zhang was also awarded the Jiangsu Province High-Level Creative Talent Strategic Award* (江蘇省高層次創新創業人才引進計劃獎) in 2011. Dr. Zhang was awarded as the "Person of the Year" at the China Healthcare Summit 2019. Dr. Zhang has published more than 20 biotechnology related scientific papers in international peer-reviewed journals and has been the inventor for more than five patents in relation to biotechnological products and/or services.

Dr. Zhang obtained a Bachelor of Engineering degree from Chengdu College of Geology* (成都地質學院) (currently known as Chengdu University of Technology* (成都理工大學)) in the PRC in July 1984 and a Master of Science degree from Nanjing University in the PRC in July 1987. He also obtained a Doctor of Philosophy degree from Duke University in the U.S. in September 1995.

Pursuant to the letter of appointment (the "**Appointment Letter**") made between Dr. Zhang and the Company, Dr. Zhang has been appointed for a term of three years commencing from 2 May 2022 and is subject to retirement by rotation and eligible for re-election pursuant to the articles of association of the Company and the Listing Rules. Pursuant to the Appointment Letter, Dr. Zhang is entitled to an annual remuneration of HK\$300,000, which has been recommended by the remuneration committee of the Company and approved by the Board with reference to his duties and responsibilities in the Company and the prevailing market conditions.

As at the date of this announcement, Dr. Zhang held approximately 36.59% of the issued share capital of GenScript Corporation (being the holding company of the Company), and was deemed, or taken to be interested in, all the shares of the Company held by GenScript Corporation for the purpose of the Securities and Futures Ordinance, which in turn GenScript Corporation held 809,577,123 shares of the Company, representing approximately 38.49% of the entire issued share capital of the Company. As at the date of this announcement, Dr. Zhang had interests in 855,941,469 shares of the Company.

Save as disclosed above, as at the date of this announcement, Dr. Zhang (i) did not hold any position with the Company or other members of the Group, (ii) did not have any interest in the Company or its associated corporation(s) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), (iii) was independent from and not related to any other Directors, members of senior management, substantial Shareholders or controlling Shareholders (as defined in the Listing Rules), and (iv) had not held any directorship in any listed companies in the last three years preceding the date of this announcement or any other major appointments and professional qualification.

Save as disclosed above, there is no matter relating to the appointment of Dr. Zhang that needs to be brought to the attention of the Shareholders and the Stock Exchange nor any information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

ESTABLISHMENT OF THE RISK MANAGEMENT COMMITTEE

The Board is pleased to announce that the Board has established the risk management committee (the “**Risk Management Committee**”) for the purposes of, among others, supporting the Board to review the effectiveness of the Company’s risk management and internal control system with effect from 2 May 2022.

Dr. Zhang, a non-executive Director, has been appointed as a member and the chairman of the Risk Management Committee; Mr. Guo Hongxin, an independent non-executive Director, and Mr. Pan Jiuan, an independent non-executive Director, have been appointed as members of the Risk Management Committee, with effect from 2 May 2022.

The terms of reference of the Risk Management Committee will be published on the Company’s website at www.genscript.com and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

ESTABLISHMENT OF THE STRATEGY COMMITTEE

The Board is pleased to announce that the Board has established the strategy committee (the “**Strategy Committee**”) for the purposes of, among others, reviewing and making recommendations on the medium-to-long-term development strategies of the Company to the Board with effect from 2 May 2022.

Dr. Zhang, a non-executive Director of the Board, has been appointed as a member and the chairman of the Strategy Committee; Mr. Pan Yuexin, a non-executive Director and Ms. Wang Jiafen, a non-executive Director, have been appointed as members of the Strategy Committee, with effect from 2 May 2022.

The terms of reference of the Strategy Committee will be published on the Company’s website at www.genscript.com and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 2 May 2022

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*